Fludeoxyglucose F-18

×

Overview

What is Fludeoxyglucose F-18?

What does Fludeoxyglucose F-18 look like?

What are the available doses of Fludeoxyglucose F-18?

Multiple-dose glass vial containing 0.74 – 11.1 GBq (20 - 300 mCi/mL) of Fludeoxyglucose F-18 Injection and 4.5 mg of sodium chloride in citrate buffer (10 mL vial: approximately 5-10 mL volume; 30 mL vial: approximately 10-30 mL volume) for intravenous administration ().

What should I talk to my health care provider before I take Fludeoxyglucose F-18?

How should I use Fludeoxyglucose F-18?

Fludeoxyglucose F-18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:

Fludeoxyglucose F-18 Injection emits radiation. Use procedures to minimize radiation exposure. Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [].

What interacts with Fludeoxyglucose F-18?

Sorry No Records found

What are the warnings of Fludeoxyglucose F-18?

Sorry No Records found

What are the precautions of Fludeoxyglucose F-18?

Sorry No Records found

What are the side effects of Fludeoxyglucose F-18?

Sorry No records found

What should I look out for while using Fludeoxyglucose F-18?

None

What might happen if I take too much Fludeoxyglucose F-18?

Sorry No Records found

How should I store and handle Fludeoxyglucose F-18?

Fludeoxyglucose F-18 Injection is supplied in a multi-dose, capped 10 mL or 30 mL glass vial containing between 0.740 – 11.1GBq/mL (20 - 300 mCi/mL), of no carrier added 2-deoxy-2-[F-18] fluoro-D-glucose, at end of synthesis, in approximately 5-10 mL volume for the 10 mL vial and approximately 10-30 mL volume for the 30 mL vial. The contents of each vial are sterile, pyrogen-free and preservative-free.NDC 65857-100-10 (10 mL)NDC 65857-100-30 (30 mL)Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements for the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.Store the Fludeoxyglucose F-18 Injection vial upright in a lead or tungsten alloy shielded container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).The expiration date and time are provided on the container label. Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS time.Fludeoxyglucose F-18 Injection is supplied in a multi-dose, capped 10 mL or 30 mL glass vial containing between 0.740 – 11.1GBq/mL (20 - 300 mCi/mL), of no carrier added 2-deoxy-2-[F-18] fluoro-D-glucose, at end of synthesis, in approximately 5-10 mL volume for the 10 mL vial and approximately 10-30 mL volume for the 30 mL vial. The contents of each vial are sterile, pyrogen-free and preservative-free.NDC 65857-100-10 (10 mL)NDC 65857-100-30 (30 mL)Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements for the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.Store the Fludeoxyglucose F-18 Injection vial upright in a lead or tungsten alloy shielded container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).The expiration date and time are provided on the container label. Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS time.Fludeoxyglucose F-18 Injection is supplied in a multi-dose, capped 10 mL or 30 mL glass vial containing between 0.740 – 11.1GBq/mL (20 - 300 mCi/mL), of no carrier added 2-deoxy-2-[F-18] fluoro-D-glucose, at end of synthesis, in approximately 5-10 mL volume for the 10 mL vial and approximately 10-30 mL volume for the 30 mL vial. The contents of each vial are sterile, pyrogen-free and preservative-free.NDC 65857-100-10 (10 mL)NDC 65857-100-30 (30 mL)Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements for the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.Store the Fludeoxyglucose F-18 Injection vial upright in a lead or tungsten alloy shielded container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).The expiration date and time are provided on the container label. Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS time.Fludeoxyglucose F-18 Injection is supplied in a multi-dose, capped 10 mL or 30 mL glass vial containing between 0.740 – 11.1GBq/mL (20 - 300 mCi/mL), of no carrier added 2-deoxy-2-[F-18] fluoro-D-glucose, at end of synthesis, in approximately 5-10 mL volume for the 10 mL vial and approximately 10-30 mL volume for the 30 mL vial. The contents of each vial are sterile, pyrogen-free and preservative-free.NDC 65857-100-10 (10 mL)NDC 65857-100-30 (30 mL)Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements for the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.Store the Fludeoxyglucose F-18 Injection vial upright in a lead or tungsten alloy shielded container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).The expiration date and time are provided on the container label. Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS time.Fludeoxyglucose F-18 Injection is supplied in a multi-dose, capped 10 mL or 30 mL glass vial containing between 0.740 – 11.1GBq/mL (20 - 300 mCi/mL), of no carrier added 2-deoxy-2-[F-18] fluoro-D-glucose, at end of synthesis, in approximately 5-10 mL volume for the 10 mL vial and approximately 10-30 mL volume for the 30 mL vial. The contents of each vial are sterile, pyrogen-free and preservative-free.NDC 65857-100-10 (10 mL)NDC 65857-100-30 (30 mL)Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements for the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.Store the Fludeoxyglucose F-18 Injection vial upright in a lead or tungsten alloy shielded container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).The expiration date and time are provided on the container label. Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS time.

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Fludeoxyglucose F-18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F-18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F-18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F-18 transport and phosphorylation (expressed as the ''lumped constant'' ratio), Fludeoxyglucose F-18 is used to assess glucose metabolism.

In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F-18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F-18 reflect greater than normal rates of glucose metabolism.

Non-Clinical Toxicology

None

The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics.

Concomitant use of clozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest.

Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately 50% when coadministered with valproate.

Concurrent administration of lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately 50% when coadministered with probenecid.

The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation.

Administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam.

Radiation-emitting products, including Fludeoxyglucose F-18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [].

Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: